BRPI1007308A2 - dicianopiridinas substituídas por alquilamino e seus profármacos de ésteres de aminoácidos - Google Patents

dicianopiridinas substituídas por alquilamino e seus profármacos de ésteres de aminoácidos

Info

Publication number: BRPI1007308A2
Authority: BR; Brazil
Prior art keywords: dicycopyridines; amino acid; acid ester; ester prodrugs; alkylamino substituted
Prior art date: 2009-01-29

Application number

BRPI1007308A

Other languages

English (en)

Inventor

Alexandros Vakalopoulos

Barbara Albrecht-Küpper

Daniel Meibom

Frank Süssmeier

Hans-Georg Lerchen

Jörg Keldenich

Katja Zimmermann

Peter Nell

Ursula Krenz

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-29

Filing date

2010-01-19

Publication date

2016-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41724154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1007308(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-01-19 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2016-02-10 Publication of BRPI1007308A2 publication Critical patent/BRPI1007308A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Crystallography & Structural Chemistry (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

BRPI1007308A 2009-01-29 2010-01-19 dicianopiridinas substituídas por alquilamino e seus profármacos de ésteres de aminoácidos BRPI1007308A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102009006602A DE102009006602A1 (de)	2009-01-29	2009-01-29	Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
PCT/EP2010/000262 WO2010086101A1 (de)	2009-01-29	2010-01-19	Alkylamino-substituierte dicyanopyridine und deren aminosäureester-prodrugs

Publications (1)

Publication Number	Publication Date
BRPI1007308A2 true BRPI1007308A2 (pt)	2016-02-10

Family

ID=41724154

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1007308A BRPI1007308A2 (pt)	2009-01-29	2010-01-19	dicianopiridinas substituídas por alquilamino e seus profármacos de ésteres de aminoácidos

Country Status (42)

Country	Link
US (3)	US8420825B2 (pt)
EP (2)	EP2391620B1 (pt)
JP (2)	JP5693469B2 (pt)
KR (2)	KR101833188B1 (pt)
CN (2)	CN102388040B (pt)
AR (1)	AR075050A1 (pt)
AU (1)	AU2010207786B2 (pt)
BR (1)	BRPI1007308A2 (pt)
CA (2)	CA2962039A1 (pt)
CO (1)	CO6400193A2 (pt)
CR (1)	CR20110407A (pt)
CU (1)	CU24037B1 (pt)
CY (2)	CY1115403T1 (pt)
DE (1)	DE102009006602A1 (pt)
DK (2)	DK2391620T3 (pt)
DO (1)	DOP2011000243A (pt)
EA (1)	EA019275B1 (pt)
EC (1)	ECSP11011235A (pt)
ES (2)	ES2473966T3 (pt)
GT (1)	GT201100205A (pt)
HK (1)	HK1211308A1 (pt)
HN (1)	HN2011002037A (pt)
HR (2)	HRP20140714T1 (pt)
HU (1)	HUE032008T2 (pt)
IL (1)	IL214019A0 (pt)
JO (1)	JO2927B1 (pt)
LT (1)	LT2743270T (pt)
MA (1)	MA33000B1 (pt)
MX (1)	MX2011007800A (pt)
MY (1)	MY156434A (pt)
NZ (1)	NZ594267A (pt)
PE (2)	PE20120430A1 (pt)
PL (2)	PL2391620T3 (pt)
PT (2)	PT2743270T (pt)
RS (1)	RS53448B (pt)
SG (1)	SG172968A1 (pt)
SI (2)	SI2743270T1 (pt)
TN (1)	TN2011000370A1 (pt)
TW (2)	TWI457126B (pt)
UA (1)	UA104613C2 (pt)
UY (1)	UY32393A (pt)
WO (1)	WO2010086101A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102004042607A1 (de)	2004-09-03	2006-03-09	Bayer Healthcare Ag	Substituierte Phenylaminothiazole und ihre Verwendung
DE102006042143A1 (de)	2006-09-08	2008-03-27	Bayer Healthcare Aktiengesellschaft	Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056740A1 (de)	2006-12-01	2008-06-05	Bayer Healthcare Ag	Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de)	2006-12-01	2008-06-05	Bayer Healthcare Ag	Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de)	2007-07-27	2009-01-29	Bayer Healthcare Ag	Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) *	2007-08-01	2009-02-05	Bayer Healthcare Aktiengesellschaft	Dipeptoid-Produgs und ihre Verwendung
DE102008013587A1 (de)	2008-03-11	2009-09-17	Bayer Schering Pharma Aktiengesellschaft	Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
JP2011520997A (ja)	2008-05-29	2011-07-21	バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト	２−アルコキシ置換ジシアノピリジン類およびそれらの使用
DE102008062567A1 (de)	2008-12-16	2010-06-17	Bayer Schering Pharma Aktiengesellschaft	Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) *	2009-01-29	2010-08-05	Bayer Schering Pharma Aktiengesellschaft	Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102010030688A1 (de)	2010-06-30	2012-01-05	Bayer Schering Pharma Aktiengesellschaft	Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) *	2010-09-02	2012-03-08	Bayer Pharma Aktiengesellschaft	Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
SG10201705097PA (en)	2012-12-21	2017-07-28	Sanofi Sa	Functionalized exendin-4 derivatives
MA39101A1 (fr) *	2013-12-12	2017-08-31	Bayer Pharma AG	Agonistes a1 de l'adénosine utilisés comme médicaments contre les maladies des reins
US9318574B2 (en)	2014-06-18	2016-04-19	International Business Machines Corporation	Method and structure for enabling high aspect ratio sacrificial gates
ES2744227T3 (es) *	2015-05-06	2020-02-24	Bayer Pharma AG	Procedimiento para la preparación de monoclorhidrato de L-alanil-L-alaninato de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridin-4-il]fenoxi}etilo
WO2017137528A1 (en)	2016-02-12	2017-08-17	Charité - Universitätsmedizin Berlin	Adenosine a1 receptor agonist for use in treatment of status epilepticus
WO2018108884A1 (de)	2016-12-16	2018-06-21	Bayer Pharma Aktiengesellschaft	Pharmazeutische tablettenformulierung
WO2018153895A1 (de)	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
WO2018153899A1 (de)	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc)
WO2018153900A1 (de) *	2017-02-22	2018-08-30	Bayer Aktiengesellschaft	Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit sglt-2-hemmern
WO2018153898A1 (de) *	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten
WO2018153897A1 (de)	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit hcn-kanal-hemmern
WO2018219804A1 (en) *	2017-06-02	2018-12-06	Bayer Pharma Aktiengesellschaft	Self-microemulsifying drug delivery systems
WO2018219801A1 (en)	2017-06-02	2018-12-06	Bayer Pharma Aktiengesellschaft	Immediate-release extrudates
WO2019180072A1 (en)	2018-03-22	2019-09-26	Bayer Pharma Aktiengesellschaft	Parenteral pharmaceutical composition comprising neladenoson bialanate
WO2021252951A1 (en)	2020-06-12	2021-12-16	Vanderbilt University	Methods of treatment for gastrointestinal motility disorders
US12029718B2 (en)	2021-11-09	2024-07-09	Cct Sciences, Llc	Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4052510A (en)	1974-12-18	1977-10-04	Sandoz, Inc.	4-alkyl-2,6-di(secondary or tertiary alkylamino) pyridines, compositions thereof and methods for treating diabetes and obesity
TW299333B (pt)	1992-12-29	1997-03-01	Takeda Pharm Industry Co Ltd
NZ284846A (en)	1994-06-16	1998-12-23	Pfizer	1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
DE4430638A1 (de)	1994-08-29	1996-03-07	Bayer Ag	Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel
JPH09132529A (ja)	1995-11-09	1997-05-20	Ono Pharmaceut Co Ltd	一酸化窒素合成酵素阻害剤
EP0876379A1 (en)	1996-01-17	1998-11-11	Novo Nordisk A/S	Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
JP4431638B2 (ja)	1996-01-29	2010-03-17	アメリカ合衆国	ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
JPH10324687A (ja)	1997-02-19	1998-12-08	Nippon Soda Co Ltd	ピロール化合物、製法および農園芸用殺菌剤
WO1998054139A1 (de)	1997-05-30	1998-12-03	Basf Aktiengesellschaft	Verfahren zur herstellung substituierter thiopyridine
JP2001510195A (ja)	1997-07-16	2001-07-31	ノボノルディスクアクティーゼルスカブ	縮合化１，２，４−チアジアジン誘導体、その調製及び使用
US6632823B1 (en)	1997-12-22	2003-10-14	Merck & Co., Inc.	Substituted pyridine compounds useful as modulators of acetylcholine receptors
DE19834044A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Neue substituierte Pyrazolderivate
DE19834047A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Substituierte Pyrazolderivate
DE19943635A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de)	1999-09-13	2001-04-12	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19947154A1 (de)	1999-10-01	2001-10-04	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
KR100521735B1 (ko)	2000-02-25	2005-10-17	에프. 호프만-라 로슈 아게	아데노신 수용체 조절인자
PL359416A1 (en)	2000-07-18	2004-08-23	Yamanouchi Pharmaceutical Co, Ltd.	Medicine comprising dicyanopyridine derivative
AR031176A1 (es)	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
JP2004515543A (ja)	2000-12-11	2004-05-27	イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー	有害無脊椎動物を防除するためのキナゾリノン類およびピリジニルピリミジノン類
ES2257461T3 (es)	2000-12-21	2006-08-01	Bristol-Myers Squibb Company	Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
DE10110438A1 (de)	2001-03-05	2002-09-19	Bayer Ag	Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110754A1 (de)	2001-03-07	2002-09-19	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110749A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10115945A1 (de)	2001-03-30	2002-10-02	Bayer Ag	Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de)	2001-03-30	2002-10-10	Bayer Ag	Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10134481A1 (de)	2001-07-16	2003-01-30	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) *	2001-12-11	2003-06-18	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
JP2003183254A (ja)	2001-12-20	2003-07-03	Yamanouchi Pharmaceut Co Ltd	２−アシルアミノ−３，５−ジシアノピリジン誘導体又はその塩
US7304061B2 (en)	2002-04-26	2007-12-04	Vertex Pharmaceuticals Incorporated	Heterocyclic inhibitors of ERK2 and uses thereof
DE10220570A1 (de)	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
WO2004013149A1 (en) *	2002-08-02	2004-02-12	Dow Global Technologies Inc.	Group 4 metal complexes containing 4-aryl-substituted, tricyclic indenyl derivatives
EP1388342A1 (en)	2002-08-07	2004-02-11	Aventis Pharma Deutschland GmbH	Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
BR0313396A (pt)	2002-08-12	2005-06-28	Sugen Inc	3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase
BR0317183A (pt)	2002-12-12	2005-11-01	Pharmacia Corp	Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
AR042667A1 (es)	2002-12-26	2005-06-29	Taisho Pharmaceutical Co Ltd	Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
TW200418829A (en)	2003-02-14	2004-10-01	Avanir Pharmaceutics	Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CA2539707C (en)	2003-09-23	2011-08-09	Merck & Co., Inc.	Quinoline potassium channel inhibitors
WO2005046603A2 (en)	2003-11-10	2005-05-26	Synta Pharmaceuticals, Corp.	Pyridine compounds
US20050182105A1 (en)	2004-02-04	2005-08-18	Nirschl Alexandra A.	Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
AU2005257486A1 (en)	2004-06-25	2006-01-05	Taisho Pharmaceutical Co., Ltd.	Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as CRF antagonists
JP2007161585A (ja)	2004-06-25	2007-06-28	Taisho Pharmaceut Co Ltd	環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
DE102004032651A1 (de)	2004-07-06	2006-02-16	Bayer Healthcare Ag	Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen
DE102004042607A1 (de) *	2004-09-03	2006-03-09	Bayer Healthcare Ag	Substituierte Phenylaminothiazole und ihre Verwendung
JP4958787B2 (ja)	2004-09-20	2012-06-20	ゼノン・ファーマシューティカルズ・インコーポレイテッド	ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
WO2006099958A1 (en)	2005-03-24	2006-09-28	Bayer Healthcare Ag	Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage
US7750015B2 (en)	2005-05-17	2010-07-06	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2007073855A1 (en)	2005-12-23	2007-07-05	Bayer Healthcare Ag	Use of adenosine a1 receptor agonists for the protection of renal cells against toxic effects caused by aminoglycosides during treatment of infectious diseases
DE102006009813A1 (de)	2006-03-01	2007-09-06	Bayer Healthcare Ag	Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel
AU2007246172A1 (en)	2006-04-28	2007-11-08	Avexa Limited	Integrase inhibitors 3
WO2008008059A1 (en)	2006-07-12	2008-01-17	Locus Pharmaceuticals, Inc.	Anti-cancer agents ans uses thereof
DE102006042143A1 (de) *	2006-09-08	2008-03-27	Bayer Healthcare Aktiengesellschaft	Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056739A1 (de)	2006-12-01	2008-06-05	Bayer Healthcare Ag	Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de)	2006-12-01	2008-06-05	Bayer Healthcare Ag	Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de) *	2007-07-27	2009-01-29	Bayer Healthcare Ag	Substituierte Aryloxazole und ihre Verwendung
DE102007036075A1 (de) *	2007-08-01	2009-02-05	Bayer Healthcare Ag	Prodrugs und ihre Verwendung
DE102007036076A1 (de)	2007-08-01	2009-02-05	Bayer Healthcare Aktiengesellschaft	Dipeptoid-Produgs und ihre Verwendung
DE102007061763A1 (de) *	2007-12-20	2009-06-25	Bayer Healthcare Ag	Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008008838A1 (de)	2008-02-13	2009-08-20	Bayer Healthcare Ag	Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung
DE102008013587A1 (de)	2008-03-11	2009-09-17	Bayer Schering Pharma Aktiengesellschaft	Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
JP2011520997A (ja)	2008-05-29	2011-07-21	バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト	２−アルコキシ置換ジシアノピリジン類およびそれらの使用
DE102008062566A1 (de)	2008-12-16	2010-06-17	Bayer Schering Pharma Aktiengesellschaft	Aminosäureester-Prodrugs und ihre Verwendung
DE102008062567A1 (de)	2008-12-16	2010-06-17	Bayer Schering Pharma Aktiengesellschaft	Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) *	2009-01-29	2010-08-05	Bayer Schering Pharma Aktiengesellschaft	Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
HUE028068T2 (en)	2009-05-01	2016-11-28	Inotek Pharmaceuticals Corp	A method for reducing the pressure in a human patient

2009
- 2009-01-29 DE DE102009006602A patent/DE102009006602A1/de not_active Withdrawn
2010
- 2010-01-19 KR KR1020177006269A patent/KR101833188B1/ko not_active Expired - Fee Related
- 2010-01-19 PT PT141555839T patent/PT2743270T/pt unknown
- 2010-01-19 ES ES10700508.4T patent/ES2473966T3/es active Active
- 2010-01-19 DK DK10700508.4T patent/DK2391620T3/da active
- 2010-01-19 WO PCT/EP2010/000262 patent/WO2010086101A1/de not_active Ceased
- 2010-01-19 MA MA34060A patent/MA33000B1/fr unknown
- 2010-01-19 DK DK14155583.9T patent/DK2743270T3/en active
- 2010-01-19 CA CA2962039A patent/CA2962039A1/en not_active Abandoned
- 2010-01-19 CA CA2750769A patent/CA2750769C/en not_active Expired - Fee Related
- 2010-01-19 EA EA201101111A patent/EA019275B1/ru not_active IP Right Cessation
- 2010-01-19 SG SG2011050770A patent/SG172968A1/en unknown
- 2010-01-19 JP JP2011546673A patent/JP5693469B2/ja not_active Expired - Fee Related
- 2010-01-19 AU AU2010207786A patent/AU2010207786B2/en not_active Ceased
- 2010-01-19 MY MYPI2011003521A patent/MY156434A/en unknown
- 2010-01-19 SI SI201031393A patent/SI2743270T1/sl unknown
- 2010-01-19 CN CN201080014887.XA patent/CN102388040B/zh not_active Expired - Fee Related
- 2010-01-19 SI SI201030685T patent/SI2391620T1/sl unknown
- 2010-01-19 KR KR1020117017725A patent/KR101717305B1/ko not_active Expired - Fee Related
- 2010-01-19 HR HRP20140714AT patent/HRP20140714T1/hr unknown
- 2010-01-19 HU HUE14155583A patent/HUE032008T2/en unknown
- 2010-01-19 PE PE2011001362A patent/PE20120430A1/es active IP Right Grant
- 2010-01-19 ES ES14155583.9T patent/ES2614702T3/es active Active
- 2010-01-19 UA UAA201110416A patent/UA104613C2/ru unknown
- 2010-01-19 PL PL10700508T patent/PL2391620T3/pl unknown
- 2010-01-19 RS RS20140393A patent/RS53448B/sr unknown
- 2010-01-19 PE PE2015000329A patent/PE20150636A1/es not_active Application Discontinuation
- 2010-01-19 PL PL14155583T patent/PL2743270T3/pl unknown
- 2010-01-19 NZ NZ594267A patent/NZ594267A/xx not_active IP Right Cessation
- 2010-01-19 PT PT107005084T patent/PT2391620E/pt unknown
- 2010-01-19 BR BRPI1007308A patent/BRPI1007308A2/pt not_active Application Discontinuation
- 2010-01-19 EP EP10700508.4A patent/EP2391620B1/de active Active
- 2010-01-19 EP EP14155583.9A patent/EP2743270B1/de active Active
- 2010-01-19 CN CN201510167727.3A patent/CN104844687B/zh not_active Expired - Fee Related
- 2010-01-19 MX MX2011007800A patent/MX2011007800A/es active IP Right Grant
- 2010-01-19 LT LTEP14155583.9T patent/LT2743270T/lt unknown
- 2010-01-26 AR ARP100100173A patent/AR075050A1/es not_active Application Discontinuation
- 2010-01-26 UY UY0001032393A patent/UY32393A/es not_active Application Discontinuation
- 2010-01-28 JO JO201023A patent/JO2927B1/en active
- 2010-01-28 TW TW099102338A patent/TWI457126B/zh not_active IP Right Cessation
- 2010-01-28 TW TW103133417A patent/TWI511968B/zh not_active IP Right Cessation
- 2010-01-29 US US12/697,000 patent/US8420825B2/en not_active Expired - Fee Related
2011
- 2011-07-11 IL IL214019A patent/IL214019A0/en not_active IP Right Cessation
- 2011-07-25 GT GT201100205A patent/GT201100205A/es unknown
- 2011-07-25 HN HN2011002037A patent/HN2011002037A/es unknown
- 2011-07-25 CO CO11092821A patent/CO6400193A2/es not_active Application Discontinuation
- 2011-07-26 EC EC2011011235A patent/ECSP11011235A/es unknown
- 2011-07-27 CR CR20110407A patent/CR20110407A/es unknown
- 2011-07-27 TN TN2011000370A patent/TN2011000370A1/fr unknown
- 2011-07-27 DO DO2011000243A patent/DOP2011000243A/es unknown
- 2011-07-28 CU CU2011000153A patent/CU24037B1/es active IP Right Grant
2013
- 2013-03-13 US US13/801,484 patent/US8772498B2/en not_active Expired - Fee Related
2014
- 2014-06-17 US US14/306,781 patent/US20140296515A1/en not_active Abandoned
- 2014-08-01 CY CY20141100585T patent/CY1115403T1/el unknown
2015
- 2015-02-03 JP JP2015019616A patent/JP5908620B2/ja active Active
- 2015-12-10 HK HK15112176.4A patent/HK1211308A1/xx unknown
2017
- 2017-02-03 CY CY20171100159T patent/CY1118601T1/el unknown
- 2017-02-08 HR HRP20170206TT patent/HRP20170206T1/hr unknown

Also Published As

Publication number	Publication date
PT2743270T (pt)	2017-02-15
TWI511968B (zh)	2015-12-11
EA201101111A1 (ru)	2012-02-28
TW201504235A (zh)	2015-02-01
JP5693469B2 (ja)	2015-04-01
MX2011007800A (es)	2011-11-18
AR075050A1 (es)	2011-03-02
CO6400193A2 (es)	2012-03-15
CN104844687B (zh)	2019-04-02
CA2750769A1 (en)	2010-08-05
EP2743270B1 (de)	2016-12-21
HRP20140714T1 (hr)	2014-11-21
CA2750769C (en)	2018-08-21
NZ594267A (en)	2013-09-27
AU2010207786A1 (en)	2011-08-25
JP2012516290A (ja)	2012-07-19
LT2743270T (lt)	2017-02-27
PE20120430A1 (es)	2012-04-21
SG172968A1 (en)	2011-08-29
CY1115403T1 (el)	2017-01-04
SI2743270T1 (sl)	2017-03-31
KR101833188B1 (ko)	2018-02-27
IL214019A0 (en)	2011-08-31
TN2011000370A1 (en)	2013-03-27
HRP20170206T1 (hr)	2017-04-07
CU20110153A7 (es)	2012-02-15
MY156434A (en)	2016-02-26
SI2391620T1 (sl)	2014-08-29
ES2473966T3 (es)	2014-07-08
HK1168353A1 (en)	2012-12-28
PL2743270T3 (pl)	2017-04-28
CN102388040B (zh)	2015-05-13
US8420825B2 (en)	2013-04-16
US8772498B2 (en)	2014-07-08
CA2962039A1 (en)	2010-08-05
UY32393A (es)	2010-08-31
KR101717305B1 (ko)	2017-03-16
US20100197609A1 (en)	2010-08-05
EP2391620B1 (de)	2014-05-07
DE102009006602A1 (de)	2010-08-05
AU2010207786B2 (en)	2015-10-22
WO2010086101A1 (de)	2010-08-05
TW201039821A (en)	2010-11-16
JP5908620B2 (ja)	2016-04-26
UA104613C2 (en)	2014-02-25
KR20110108377A (ko)	2011-10-05
KR20170029029A (ko)	2017-03-14
US20130267700A1 (en)	2013-10-10
PL2391620T3 (pl)	2014-09-30
EP2743270A1 (de)	2014-06-18
EA019275B1 (ru)	2014-02-28
GT201100205A (es)	2013-08-21
CN104844687A (zh)	2015-08-19
JP2015120727A (ja)	2015-07-02
HUE032008T2 (en)	2017-08-28
MA33000B1 (fr)	2012-01-02
EP2391620A1 (de)	2011-12-07
CN102388040A (zh)	2012-03-21
RS53448B (sr)	2014-12-31
PT2391620E (pt)	2014-06-25
TWI457126B (zh)	2014-10-21
CU24037B1 (es)	2014-11-27
DK2391620T3 (da)	2014-08-11
US20140296515A1 (en)	2014-10-02
ES2614702T3 (es)	2017-06-01
CY1118601T1 (el)	2017-07-12
HK1211308A1 (en)	2016-05-20
CR20110407A (es)	2012-01-02
ECSP11011235A (es)	2011-10-31
DK2743270T3 (en)	2017-02-20
DOP2011000243A (es)	2017-10-15
JO2927B1 (en)	2015-09-15
HN2011002037A (es)	2013-12-02
PE20150636A1 (es)	2015-05-08

Legal Events

Date	Code	Title	Description
2016-06-07	B25A	Requested transfer of rights approved	Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-15	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-10-02	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-09-10	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-01-21	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
2021-06-01	B350	Update of information on the portal [chapter 15.35 patent gazette]

Publication	Publication Date	Title
BRPI1007308A2 (pt)	2016-02-10	dicianopiridinas substituídas por alquilamino e seus profármacos de ésteres de aminoácidos
LT3037089T (lt)	2020-01-10	Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
EP2442645A4 (en)	2013-03-06	choline
BRPI1009192A2 (pt)	2015-09-22	preparação de ácido adípico
BRPI1015238A2 (pt)	2019-09-24	diamidas de azetidilina como inibidores de monoaciglicerol lipase
EP2401367A4 (en)	2012-11-07	HYPERACTIVE PIGGYBAC TRANSPOSASES
BR112012008164A2 (pt)	2018-06-05	método para a preparação de ácido 2,5-furanodicarbloxílico e seus ésteres
EP2520259A4 (en)	2013-10-30	DIAPER
HRP20181347T1 (hr)	2018-10-19	Formulacije dvoslojne tablete
PT2473528E (pt)	2015-03-04	Formulações estáveis de polipéptidos e seus usos
EP2504020A4 (en)	2013-05-29	Daptomycin FORMULATIONS
EP2476717A4 (en)	2013-01-02	POLYAMIDE AND POLYAMIDE COMPOSITION
BRPI1011650A2 (pt)	2016-03-22	composições sólidas compreendendo ácido 5-aminolevulínico
BRPI1007196A2 (pt)	2016-09-27	profármacos e derivado de espiroindolinona
BRPI1008063A2 (pt)	2015-08-25	Agonistas sinteticas de tlr9
BRPI1007413A2 (pt)	2015-08-25	Composição compreendendo ácido caftárico e/ou seus derivados
BRPI1014529A2 (pt)	2015-08-25	Composições de monoglicerídeo de ácido graxo
BRPI1016067A2 (pt)	2019-09-24	ésteres e seus usos.
BR112012004105A2 (pt)	2017-06-20	pró-fármacos de bisfosfonato
BR112012001551A2 (pt)	2017-07-11	profármacos de aminoácido galantamina e peptídeo e usos dos mesmos
EP2646035A4 (en)	2014-05-07	PRODRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4- (METHYLPYRIDINE-2- (1H-) ON AND DERIVATIVES THEREOF
BRMU9002694U2 (pt)	2014-04-08	Elemento de tração
EP2542232A4 (en)	2013-08-28	FATTY ACID INHIBITORS
FR2964937B1 (fr)	2013-07-12	Triporteur et direction de triporteur
BRPI1014810A2 (pt)	2015-08-25	Métodos e formulações ectoparasiticidas